Physician profile
Edwin Liu
NPI 1619970738
$5,454.34
in general payments reported to CMS, 2019-2025
18 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $1,222 · 2021: $3,250 · 2022: $177 · 2023: $208 · 2024: $280 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.82 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $4,505.92 | 2020-2024 | Valtoco |
| Greenwich Biosciences, INC. | $163.31 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $136.50 | 2023-2024 | Qelbree, Qelbree |
| Ucb, INC. | $105.02 | 2020-2025 | Fintepla |
| Harmony Biosciences LLC | $104.68 | 2025 | |
| Emd Serono, INC. | $96.75 | 2022 | |
| Jazz Pharmaceuticals INC. | $86.98 | 2023-2024 | |
| Boston Scientific Corporation | $40.60 | 2022 | |
| Biomarin Pharmaceutical INC. | $34.81 | 2024 | Brineura |
| Sk Life Science, INC. | $33.58 | 2023 | |
| Immedica Pharma US, INC. | $30.21 | 2024 | |
| Aucta Pharmaceuticals, INC. | $24.42 | 2024 | Motpoly Xr |
| Biocodex, INC. | $23.42 | 2023 | Diacomit |
| Tris Pharma INC | $22.96 | 2025 | Onyda Xr |
| Catalyst Pharmaceuticals, INC. | $21.54 | 2023 | Fycompa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.32 | 2024 | Evrysdi |
| Travere Therapeutics, INC. | $3.32 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.